This Anti-Corruption Helpdesk brief was produced in response to a query from a U4 Partner Agency. The U4 Helpdesk is operated by Transparency International in collaboration with the U4 Anti-Corruption Resource Centre based at the Chr. Michelsen Institute.
Query
What are the corruption risks associated with vaccine research and clinical trials, particularly in low-income countries? Which measures can be taken to limit these risks?
Clinical trials that take place in a range of countries ensures that vaccines are effective for different populations and bring opportunities for researchers and investment into a country’s medical infrastructure and equipment. However, corruption risks can disrupt and dissuade vaccine research, particularly in lower income countries. To mitigate this, several integrity measures can be put into place to ensure that clinical trials are conducted safely, transparently and effectively.
Contents
- Background
- Corruption risks
- Undue influence
- Misappropriation of funds
- Evidence distortion and conflicts of interest
- Other ethical concerns
- Integrity measures
- Ethical principles
- Regulatory oversight and agencies
- Trial site selection
- Risk management frameworks
- Oversight during the clinical trial
- Whistleblower channels and community complaints mechanisms
- Transparency
- References
Authors
Caitlin Maslen
Reviewers
Jamie Bergin (TI)
Daniel Sejerøe Hausenkamph (U4)
Jonathan Cushing (TI Global Health)
Date
13/11/2024
